论文部分内容阅读
目的 观察重组葡激酶 (recombinant staphylokinase,r- Sak)治疗实验性视网膜中央动脉阻塞(central retinal artery occlusion,CRAO)的效果及其对全身的影响。 方法 15只猫 (30只眼 )静脉注射光化学药物 3%孟加拉红后 ,用氩绿激光照射视网膜动脉形成阻塞模型 ,静脉给予 r- Sak和尿激酶 (urokinase,U K)溶栓 ,通过荧光素眼底血管造影判断动脉再通情况 ,同时作血液生化指标的检查。 结果 成功地建立了 CRAO模型 ,实验用药给药 4h后 ,r- Sak组 CRAO的完全再通率为 10 0 % ,而 UK组的完全再通率仅为6 0 %。使用 r- Sak后血液中凝血、纤溶、抗纤溶指标与空白对照组比较均差异无显著意义。 结论 光化学法可建立和临床相似的 CRAO模型 ,R- Sak是一种高效安全、特异性强的溶栓药 ,在临床治疗 CRAO上有较好的应用前景。
Objective To investigate the effect of recombinant staphylokinase (r-Sak) on experimental central retinal artery occlusion (CRAO) and its effect on the whole body. METHODS: Fifteen cats (30 eyes) were intravenously injected with 3% Bengal red, and the retinal artery was irradiated with argon-green laser to form an occlusion model. R-Sak and urokinase (UK) Angiography to determine the situation of recanalization, blood biochemical indicators for the same time check. Results The model of CRAO was established successfully. After 4h of administration, the complete recanalization rate of CRAO in r-Sak group was 100%, while the complete recanalization rate in UK group was only 60%. After r-Sak blood coagulation, fibrinolysis, anti-fibrinolysis indicators compared with the blank control group were no significant difference. Conclusion Photochemical method can establish CRAO model which is similar to clinic. R-Sak is a kind of thrombolytic drugs with high efficiency, safety and specificity. It has good application prospect in the clinical treatment of CRAO.